Kfar Saba, Israel (ots/PRNewswire) - CartiHeal Ltd., developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee-joints, today announced its first commercial implantation of Agili-C in the US by Dr. Ken Zaslav, a specialist in Orthopedic Surgery and Sports Medicine at Northwell Health in New York City, NY. The ...
Aachen (ots) - - Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. - Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid ...
Aachen, Germany (ots) - - Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovative non-opioid investigational medicine. - The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. - Globally, more than 300 million patients ...
Aachen (ots) - Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin ("RTX"). Shionogi obtained the exclusive rights to commercialise Grünenthal's asset in Japan for pain associated with osteoarthritis of the knee. RTX ...
Aachen, Germany (ots) - - Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. - NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. - Grünenthal has invested over € 2 billion in successful M&A ...
Aachen, Germany, and Raleigh, North Carolina (ots) - Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients ...
Brussels/Aachen (ots) - - Five promising early-career scientists have been awarded the prestigious EFIC-Grünenthal Grant (E-G-G) 2022 - The E-G-G funds innovative research projects to advance understanding of pain, and improve the lives of people with pain The European Pain Federation EFIC® and the pharmaceutical company Grünenthal have announced the five recipients ...
